Albertí-Valls Manel, Megino-Luque Cristina, Macià Anna, Gatius Sònia, Matias-Guiu Xavier, Eritja Núria
Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Av. Rovira Roure 80, 25198 Lleida, Spain.
Department of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Cancers (Basel). 2023 Dec 29;16(1):185. doi: 10.3390/cancers16010185.
Endometrial cancer, the most prevalent gynecological malignancy in developed countries, is experiencing a sustained rise in both its incidence and mortality rates, primarily attributed to extended life expectancy and lifestyle factors. Currently, the absence of precise diagnostic tools hampers the effective management of the expanding population of women at risk of developing this disease. Furthermore, patients diagnosed with endometrial cancer require precise risk stratification to align with optimal treatment planning. Metabolomics technology offers a unique insight into the molecular landscape of endometrial cancer, providing a promising approach to address these unmet needs. This comprehensive literature review initiates with an overview of metabolomic technologies and their intrinsic workflow components, aiming to establish a fundamental understanding for the readers. Subsequently, a detailed exploration of the existing body of research is undertaken with the objective of identifying metabolite biomarkers capable of enhancing current strategies for endometrial cancer diagnosis, prognosis, and recurrence monitoring. Metabolomics holds vast potential to revolutionize the management of endometrial cancer by providing accuracy and valuable insights into crucial aspects.
子宫内膜癌是发达国家最常见的妇科恶性肿瘤，其发病率和死亡率持续上升，主要归因于预期寿命延长和生活方式因素。目前，缺乏精确的诊断工具阻碍了对越来越多有患此病风险的女性进行有效管理。此外，被诊断为子宫内膜癌的患者需要精确的风险分层，以便与最佳治疗方案相匹配。代谢组学技术为子宫内膜癌的分子格局提供了独特的见解，为满足这些未被满足的需求提供了一种很有前景的方法。这篇全面的文献综述首先概述了代谢组学技术及其内在的工作流程组成部分，旨在为读者建立基本的理解。随后，对现有研究进行了详细探讨，目的是识别能够改进当前子宫内膜癌诊断、预后和复发监测策略的代谢物生物标志物。代谢组学通过提供准确性和对关键方面的宝贵见解，在革新子宫内膜癌管理方面具有巨大潜力。
